Nouveau Biosciences Announces the Appointment of Michael Maitland, M.D., Ph.D. to its Scientific Advisory Board

[New York, NY – October 21, 2026] – Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has appointed the renowned physician-scientist Michael Maitland, M.D., Ph.D. to its Scientific Advisory Board.

Dr. Maitland is an internationally recognized physician-scientist specializing in the early-phase development of novel therapies. He was previously the Vice President of Clinical Development at Pathos AI and, before that, Medical Lead for CRISPR-based therapies (lonvoguran ziclumeran/NTLA-2002 and nexiguran ziclumeran/NTLA-2001) at Intellia Therapeutics. Michael brings vast experience across the entire spectrum of Nouveau's focus, including the use of AI and development of nanotherapeutics. His expertise in developing CRISPR-based therapeutics brings an important dimension to the company's interest.

"I have had the pleasure of watching and working with Michael over the past 2 decades. When it comes to thinking 'outside-the-box', it is hard to find a more innovative person who can so seamlessly traverse the basic science – clinical divide. Couple this to his command of pharmacology, pharmacokinetic modeling and regulatory processes, and you have exactly the kind of person Nouveau is looking to for critical insights into its transformative drugs", said Owen A. O'Connor, M.D., Ph.D., Founder and CEO of Nouveau Biosciences.

"Novueau has managed to take a variety of established tools and integrate them in unprecedented fashion to solve important clinical problems. Their use of a genomic- and AI-based discovery platform coupled to the well-established principles in polymer nanomedicine first developed by Dr. Langer, could well change the landscape in drug development" says Dr. Maitland. "I am really honored to work alongside the remarkably talented team Dr. O'Connor has assembled and look forward to helping the company build what I believe will be an important platform to the future of drug discovery and development".

Dr. Maitland has held leadership roles on Investigational Drugs for multiple major academic cancer centers, and for the National Cancer Institute, including the Alliance and NRG cooperative groups. Importantly, he is a leading authority on conducting research across interdisciplinary teams and addressing regulatory and safety questions that accompany innovative therapeutic strategies.

About Nouveau Biosciences

Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology, the *Nouveau Nexus*™, that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company's lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies' future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact

media@nouveaubiosciences.com